KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Capital Expenditures (2016 - 2025)

Pfizer (PFE) has disclosed Capital Expenditures for 17 consecutive years, with $845.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 7.85% to $845.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 billion, a 9.63% decrease, with the full-year FY2025 number at $2.6 billion, down 9.63% from a year prior.
  • Capital Expenditures was $845.0 million for Q4 2025 at Pfizer, up from $602.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.2 billion in Q4 2022 to a low of $537.0 million in Q3 2021.
  • A 5-year average of $881.9 million and a median of $727.5 million in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 77.14% in 2023; the steepest drop was 63.76% in 2023.
  • Pfizer's Capital Expenditures stood at $1.7 billion in 2021, then skyrocketed by 30.78% to $2.2 billion in 2022, then plummeted by 53.29% to $1.0 billion in 2023, then dropped by 12.16% to $917.0 million in 2024, then dropped by 7.85% to $845.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Capital Expenditures are $845.0 million (Q4 2025), $602.0 million (Q3 2025), and $618.0 million (Q2 2025).